United States v. Otuonye

995 F.3d 1191
CourtCourt of Appeals for the Tenth Circuit
DecidedMay 4, 2021
Docket19-3250
StatusPublished
Cited by22 cases

This text of 995 F.3d 1191 (United States v. Otuonye) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Otuonye, 995 F.3d 1191 (10th Cir. 2021).

Opinion

FILED United States Court of Appeals PUBLISH Tenth Circuit

UNITED STATES COURT OF APPEALS May 4, 2021

Christopher M. Wolpert FOR THE TENTH CIRCUIT Clerk of Court _________________________________

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v. No. 19-3250

EBUBE OTUONYE,

Defendant - Appellant. _________________________________

Appeal from the United States District Court for the District of Kansas (D.C. No. 6:18-CR-10085-EFM-1) _________________________________

Michael D. Kimerer, Kimerer Law Group, P.C., Phoenix, Arizona, for Defendant – Appellant.

James A. Brown, Assistant United States Attorney (Stephen R. McAllister, United States Attorney with him on the brief), Topeka, Kansas, for Plaintiff – Appellee. _________________________________

Before MATHESON, BALDOCK, and MORITZ, Circuit Judges. _________________________________

MATHESON, Circuit Judge. _________________________________

Wichita pharmacist Ebube Otuonye filled prescriptions written by Dr. Steven

Henson for opioids and other controlled substances. The Drug Enforcement

Administration (“DEA”) became suspicious of Dr. Henson’s prescriptions and

investigated him, which led them to Mr. Otuonye. Based on the results of the DEA’s investigation, Mr. Otuonye was indicted for

conspiring to unlawfully distribute controlled substances under 21 U.S.C. § 846 (Count

1); unlawfully distributing controlled substances under 21 U.S.C. § 841(a)(1), (b)(1)(C),

and 18 U.S.C. § 2 (Count 2); and Medicare and Medicaid fraud in violation of 18 U.S.C.

§ 1347 (Counts 3 and 4). A jury convicted Mr. Otuonye on all four counts. The district

court imposed a 150-month concurrent prison sentence.

Mr. Otuonye raises seven issues on appeal. Five challenge the admission of

evidence. The sixth challenges the sufficiency of the evidence for all four convictions.

Finally, Mr. Otuonye argues the district court committed procedural error by

miscalculating his sentencing guidelines range.

Exercising jurisdiction under 28 U.S.C. § 1291 and 18 U.S.C. § 3742(a), we

affirm.

I. BACKGROUND

A. Legal Background

The Controlled Substances Act (“CSA”), 21 U.S.C. §§ 801-904, classifies

controlled substances into five drug schedules based on their medical use and potential

for abuse. Oxycodone, methadone, and hydromorphone, which have accepted medical

uses but are highly addictive, are classified as Schedule II drugs. 21 C.F.R.

§ 1308.12(b)(1), (c). Alprazolam, a central nervous system depressant used to treat

insomnia and anxiety, is classified as a Schedule IV drug. 21 C.F.R. § 1308.14(c)(2).

Title 21 U.S.C. § 841(a)(1) makes it unlawful, except under circumstances

authorized by the statute, “for any person knowingly or intentionally . . . to manufacture,

2 distribute, or dispense, or possess with intent to manufacture, distribute, or dispense, a

controlled substance.” But 21 U.S.C. § 829 provides an exception allowing licensed,

registered, or permitted practitioners to prescribe controlled substances in four of the five

schedules, including Schedule II and Schedule IV. See 21 U.S.C. § 802(21) (defining a

“practitioner” who may prescribe controlled substances).

DEA regulations implementing 21 U.S.C. § 829 specify:

A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.

21 C.F.R. § 1306.4(a) (emphasis added). Thus, a pharmacist violates the CSA by

distributing controlled substances in a manner inconsistent with the usual course of

contemporary medical practice. See United States v. Lovern, 590 F.3d 1095, 1101

(10th Cir. 2009).

B. Factual Background

DEA Investigation

In October 2014, the DEA began receiving phone calls from Wichita-area

pharmacists raising concerns about the prescribing patterns of Dr. Henson—particularly

his prescribing high doses of opioids and combining opioids with benzodiazepines such

as Xanax (alprazolam). DEA Task Force Officer (“TFO”) Mikeal Long testified at trial

that, in addition to the types and doses of drugs being prescribed, the fact that “[p]atients

were coming from all over to see Dr. Henson” raised suspicion. Jt. App., Vol. 7 at 1550.

3 The DEA also observed several other red flags. For example, Dr. Henson’s patients often

paid in cash. And once a pharmacy filled one prescription written by Dr. Henson, many

of his patients would come later that day or the following day to have their prescriptions

filled, suggesting coordination among patients.

a. Neighborhood Pharmacy

Through surveillance of Dr. Henson, the DEA identified a group of individuals

who would drive from Kansas City, Lawrence, or Topeka to Wichita to buy prescriptions

from Dr. Henson, have them filled at pharmacies, and sell the pills on the street.1

The DEA confronted Amanda Terwilleger, a member of that group. Ms.

Terwilleger told investigators that some pharmacists refused to fill Dr. Henson’s

prescriptions, so she took her prescriptions to Neighborhood Pharmacy in Wichita. But

Neighborhood had a policy requiring customers to fill three non-controlled prescriptions

for every controlled prescription. Ms. Terwilleger did not have any non-controlled

prescriptions.

Neighborhood Pharmacy was a retail pharmacy owned and operated by Mr.

Otuonye, its pharmacist-in-charge. It was licensed by the Kansas Board of Pharmacy and

the DEA to distribute controlled substances.

1 The DEA also later identified a second such group from the Newton, Kansas area, spearheaded by Nick McGovern, a Dr. Henson patient. Mr. McGovern reportedly recruited others to go to Dr. Henson to get prescriptions. He would retain a portion of the drugs. Associates of Mr. McGovern testified at trial.

4 The DEA interviewed several other patients of Dr. Henson who reported they had

difficulty filling Dr. Henson’s prescriptions at other pharmacies but were able to fill them

at Neighborhood Pharmacy.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Back
Tenth Circuit, 2026
United States v. Otuonye
Tenth Circuit, 2026
United States v. Tonya Robinson
Seventh Circuit, 2025
United States v. Albert Smith
Seventh Circuit, 2025
United States v. Butler (G'Ante)
141 F.4th 1136 (Tenth Circuit, 2025)
United States v. Rivera
Tenth Circuit, 2025
United States v. Taylor
Tenth Circuit, 2025
United States v. Pritchett
Tenth Circuit, 2025
Tyler v. United States
W.D. Oklahoma, 2025
Coleman v. Smith
D. Maryland, 2024
United States v. Moss
Tenth Circuit, 2024
United States v. McFadden
116 F.4th 1069 (Tenth Circuit, 2024)
Varnell v. United States
W.D. Oklahoma, 2024
United States v. Veneno
94 F.4th 1196 (Tenth Circuit, 2024)
United States v. Ferguson
Tenth Circuit, 2022
Cano v. Williams
Tenth Circuit, 2022

Cite This Page — Counsel Stack

Bluebook (online)
995 F.3d 1191, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-otuonye-ca10-2021.